Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer

Molecular Therapy

Volumn 16, Issue 5, 2008, Pages 979-984

  Galanis, Evanthia ^a   Carlson, Stephanie K ^a   Foster, Nathan R ^a   Lowe, Val ^a   Quevedo, Fernando ^a   McWilliams, Robert R ^a   Grothey, Axel ^a   Jatoi, Aminah ^a   Alberts, Steven R ^a   Rubin, Joseph ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CA 19-9 ANTIGEN; CYCLIN G1; GEMCITABINE; NEUTRALIZING ANTIBODY; RETROVIRUS VECTOR; REXIN G;

ABDOMINAL DISTENSION; ADULT; AGED; ANOREXIA; ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FLUSHING; HUMAN; HUMAN CELL; HYPERMAGNESEMIA; IMMUNE RESPONSE; INSOMNIA; MALE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SIDE EFFECT; SURVIVAL TIME; TRANSAMINITIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS DETECTION; VIRUS DNA CELL DNA INTERACTION; VIRUS REPLICATION;

REPLICATION COMPETENT VIRUSES;

EID: 42549139673     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.29     Document Type: Article

References (17)

1. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966
2. FL Hall L Liu NL Zhu M Stapfer WF Anderson RW Beart Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor Hum Gene Ther 11 2000 983 993
3. EM Gordon PX Liu ZH Chen L Liu MD Whitley C Gee Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct Cancer Res 60 2000 3343 3347
4. C Swanton Cell-cycle targeted therapies Lancet Oncol 5 2004 27 36
5. G Hung MJ Skotzko M Chang NL Zhu D Parekh FL Hall Intratumoral injection of an antisense cyclin G1 retroviral vector inhibits growth of undifferentiated carcinoma xenografts in nude mice Int J Pediatr Hematol Oncol 4 1997 317 325
6. EM Gordon GH Cornelio CC Lorenzo 3rd JP Levy RA Reed L Liu First clinical experience using a “pathotropic” injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer Int J Oncol 24 2004 177 185
7. H Choi C Charnsangavej SC Faria HA Macapinlac MA Burgess SR Patel Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 2007 1753 1759
8. RS Benjamin H Choi HA Macapinlac MA Burgess SR Patel LL Chen We should resist using RECIST, at least in GIST J Clin Oncol 25 2007 1760 1764
9. A Jemal R Siegel E Ward T Murray J Xu MJ Thun Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66
10. HA Burris 3rd MJ Moore J Andersen MR Green ML Rothenberg MR Modiano Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
11. EM Gordon FF Lopez GH Cornelio CC Lorenzo 3rd JP Levy RA Reed Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience Int J Oncol 29 2006 1053 1064
12. M Morse Technology evaluation: Rexin-G, Epeius Biotechnologies Curr Opin Mol Ther 7 2005 164 169
13. BE Storer Design and analysis of phase I clinical trials Biometrics 45 1989 925 937
14. EL Kaplan P Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
15. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
16. M Skotzko L Wu WF Anderson EM Gordon FL Hall Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells Cancer Res 55 1995 5493 5498
17. N Tabata M Miyazawa R Fujisawa YA Takei H Abe K Hashimoto Establishment of monoclonal anti-retroviral gp70 autoantibodies from MRL/lpr lupus mice and induction of glomerular gp70 deposition and pathology by transfer into non-autoimmune mice J Virol 74 2000 4116 4126